Switch to:
Also traded in: Germany, South Africa

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.24
APNHF's Cash to Debt is ranked lower than
86% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. APNHF: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
APNHF' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 0.36 Max: N/A
Current: 0.24
Equity to Asset 0.41
APNHF's Equity to Asset is ranked lower than
78% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. APNHF: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
APNHF' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.50 Max: 0.55
Current: 0.41
0.31
0.55
Interest Coverage 4.95
APNHF's Interest Coverage is ranked lower than
75% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. APNHF: 4.95 )
Ranked among companies with meaningful Interest Coverage only.
APNHF' s Interest Coverage Range Over the Past 10 Years
Min: 3.12  Med: 5.14 Max: 8.52
Current: 4.95
3.12
8.52
F-Score: 4
Z-Score: 2.83
M-Score: -2.29
WACC vs ROIC
4.81%
11.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 28.70
APNHF's Operating margin (%) is ranked higher than
90% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. APNHF: 28.70 )
Ranked among companies with meaningful Operating margin (%) only.
APNHF' s Operating margin (%) Range Over the Past 10 Years
Min: 23.39  Med: 25.80 Max: 28.07
Current: 28.7
23.39
28.07
Net-margin (%) 17.02
APNHF's Net-margin (%) is ranked higher than
83% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. APNHF: 17.02 )
Ranked among companies with meaningful Net-margin (%) only.
APNHF' s Net-margin (%) Range Over the Past 10 Years
Min: 14.4  Med: 18.03 Max: 20.91
Current: 17.02
14.4
20.91
ROE (%) 16.82
APNHF's ROE (%) is ranked higher than
78% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. APNHF: 16.82 )
Ranked among companies with meaningful ROE (%) only.
APNHF' s ROE (%) Range Over the Past 10 Years
Min: 16.51  Med: 24.04 Max: 38.57
Current: 16.82
16.51
38.57
ROA (%) 6.50
APNHF's ROA (%) is ranked higher than
64% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. APNHF: 6.50 )
Ranked among companies with meaningful ROA (%) only.
APNHF' s ROA (%) Range Over the Past 10 Years
Min: 6.08  Med: 10.37 Max: 17.2
Current: 6.5
6.08
17.2
ROC (Joel Greenblatt) (%) 43.79
APNHF's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. APNHF: 43.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
APNHF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 37.42  Med: 70.80 Max: 177.54
Current: 43.79
37.42
177.54
Revenue Growth (3Y)(%) 33.20
APNHF's Revenue Growth (3Y)(%) is ranked higher than
92% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. APNHF: 33.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
APNHF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 14.9  Med: 24.75 Max: 33.4
Current: 33.2
14.9
33.4
EBITDA Growth (3Y)(%) 34.30
APNHF's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. APNHF: 34.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
APNHF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 25.00 Max: 37.9
Current: 34.3
0
37.9
EPS Growth (3Y)(%) 24.70
APNHF's EPS Growth (3Y)(%) is ranked higher than
77% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. APNHF: 24.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
APNHF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 17.8  Med: 26.55 Max: 33.9
Current: 24.7
17.8
33.9
» APNHF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with APNHF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:LDZA.Germany, APN.South Africa,
Aspen Pharmacare Holdings Ltd through its subsidiaries, is engaged in manufacturing, marketing and distribution of branded and generic pharmaceutical, as well as nutritional products.

Aspen Pharmacare Holdings Ltd is a pharmaceutical company. The Company, through its subsidiaries, is engaged in the manufacture, marketing and distribution of branded and generic pharmaceutical, as well as consumer, OTC and nutritional products in selected territories, operating primarily in the healthcare industry. Its product types includes tablets, capsules, eye drops, injectable products (including lyophilized vials), oral contraceptives, form-filled seals, suppositories, liquids, creams, ointments, infant nutritional products, and specialist active pharmaceutical ingredients. The Company operates in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, France, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America.

Ratios

vs
industry
vs
history
P/E(ttm) 23.39
APNHF's P/E(ttm) is ranked higher than
57% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. APNHF: 23.39 )
Ranked among companies with meaningful P/E(ttm) only.
APNHF' s P/E(ttm) Range Over the Past 10 Years
Min: 12.7  Med: 20.37 Max: 39.98
Current: 23.39
12.7
39.98
Forward P/E 68.49
APNHF's Forward P/E is ranked lower than
97% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. APNHF: 68.49 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.37
APNHF's PE(NRI) is ranked higher than
58% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.81 vs. APNHF: 23.37 )
Ranked among companies with meaningful PE(NRI) only.
APNHF' s PE(NRI) Range Over the Past 10 Years
Min: 13.24  Med: 21.81 Max: 39.98
Current: 23.37
13.24
39.98
Price/Owner Earnings (ttm) 45.32
APNHF's Price/Owner Earnings (ttm) is ranked lower than
62% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.19 vs. APNHF: 45.32 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
APNHF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 20.67  Med: 45.71 Max: 133.34
Current: 45.32
20.67
133.34
P/B 3.28
APNHF's P/B is ranked lower than
58% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. APNHF: 3.28 )
Ranked among companies with meaningful P/B only.
APNHF' s P/B Range Over the Past 10 Years
Min: 2.66  Med: 4.72 Max: 8.41
Current: 3.28
2.66
8.41
P/S 3.92
APNHF's P/S is ranked lower than
61% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. APNHF: 3.92 )
Ranked among companies with meaningful P/S only.
APNHF' s P/S Range Over the Past 10 Years
Min: 2.26  Med: 3.79 Max: 6.78
Current: 3.92
2.26
6.78
PFCF 58.51
APNHF's PFCF is ranked lower than
73% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. APNHF: 58.51 )
Ranked among companies with meaningful PFCF only.
APNHF' s PFCF Range Over the Past 10 Years
Min: 17.7  Med: 59.01 Max: 341.82
Current: 58.51
17.7
341.82
POCF 29.28
APNHF's POCF is ranked lower than
68% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. APNHF: 29.28 )
Ranked among companies with meaningful POCF only.
APNHF' s POCF Range Over the Past 10 Years
Min: 13.06  Med: 23.14 Max: 52.18
Current: 29.28
13.06
52.18
EV-to-EBIT 16.99
APNHF's EV-to-EBIT is ranked higher than
60% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. APNHF: 16.99 )
Ranked among companies with meaningful EV-to-EBIT only.
APNHF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 15.00 Max: 31
Current: 16.99
6.8
31
EV-to-EBITDA 15.15
APNHF's EV-to-EBITDA is ranked higher than
56% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. APNHF: 15.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
APNHF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 14.30 Max: 31
Current: 15.15
6.8
31
PEG 1.11
APNHF's PEG is ranked higher than
67% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. APNHF: 1.11 )
Ranked among companies with meaningful PEG only.
APNHF' s PEG Range Over the Past 10 Years
Min: 0.4  Med: 0.83 Max: 2.28
Current: 1.11
0.4
2.28
Shiller P/E 52.53
APNHF's Shiller P/E is ranked lower than
58% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.77 vs. APNHF: 52.53 )
Ranked among companies with meaningful Shiller P/E only.
APNHF' s Shiller P/E Range Over the Past 10 Years
Min: 42.47  Med: 63.45 Max: 88.82
Current: 52.53
42.47
88.82
Current Ratio 0.89
APNHF's Current Ratio is ranked lower than
91% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. APNHF: 0.89 )
Ranked among companies with meaningful Current Ratio only.
APNHF' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.35 Max: 1.95
Current: 0.89
0.7
1.95
Quick Ratio 0.56
APNHF's Quick Ratio is ranked lower than
94% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. APNHF: 0.56 )
Ranked among companies with meaningful Quick Ratio only.
APNHF' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.97 Max: 1.31
Current: 0.56
0.49
1.31
Days Inventory 231.15
APNHF's Days Inventory is ranked lower than
87% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. APNHF: 231.15 )
Ranked among companies with meaningful Days Inventory only.
APNHF' s Days Inventory Range Over the Past 10 Years
Min: 114.46  Med: 134.65 Max: 203.72
Current: 231.15
114.46
203.72

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.26
APNHF's Price/Projected FCF is ranked lower than
99.99% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. APNHF: 3.26 )
Ranked among companies with meaningful Price/Projected FCF only.
APNHF' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.01  Med: 2.38 Max: 5.09
Current: 3.26
1.01
5.09
Price/DCF (Earnings Based) 0.82
APNHF's Price/DCF (Earnings Based) is ranked higher than
74% of the 70 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. APNHF: 0.82 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.03
APNHF's Price/Median PS Value is ranked lower than
99.99% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. APNHF: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
APNHF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 0.66 Max: 1.03
Current: 1.03
0.32
1.03
Price/Peter Lynch Fair Value 1.11
APNHF's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. APNHF: 1.11 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
APNHF' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.35  Med: 0.58 Max: 0.86
Current: 1.11
0.35
0.86
Earnings Yield (Greenblatt) (%) 5.90
APNHF's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. APNHF: 5.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
APNHF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.2  Med: 6.70 Max: 14.8
Current: 5.9
3.2
14.8
Forward Rate of Return (Yacktman) (%) 25.24
APNHF's Forward Rate of Return (Yacktman) (%) is ranked higher than
84% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. APNHF: 25.24 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
APNHF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.6  Med: 26.60 Max: 35.5
Current: 25.24
1.6
35.5

More Statistics

Revenue (TTM) (Mil) $2,278
EPS (TTM) $ 0.85
Beta2.11
Short Percentage of Float0.00%
52-Week Range $18.37 - 72.66
Shares Outstanding (Mil)456.06

Analyst Estimate

Jun16 Jun17 Jun18
Revenue (Mil $) 2,860 3,269 3,751
EPS ($) 0.27 0.33 0.41
EPS without NRI ($) 0.27 0.33 0.41
EPS Growth Rate
(3Y to 5Y Estimate)
N/A

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)